Carregant...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Chinês |
| Publicat: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Col·lecció: | Chinese Journal of Lung Cancer |
| Matèries: | |
| Accés en línia: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|